BioWest Therapeutics Inc
Quick facts
Phase 3 pipeline
- MBI 226 · Oncology
MBI 226 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to enhance anti-tumor immunity or reduce pathological inflammation.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: